Data updated: Mar 10, 2026
ENTEREG
ALVIMOPAN
Approved 2008-05-20
2
Indications
--
Phase 3 Trials
17
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2008-05-20
- Routes
- ORAL
- Dosage Forms
- CAPSULE
ENTEREG Approval History
Loading approval history...
What ENTEREG Treats
2 FDA approvalsOriginally approved for its first indication in 2008 . Covers 2 distinct patient populations.
- Other (2)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ENTEREG FDA Label Details
ProENTEREG Patents & Exclusivity
Latest Patent: Feb 2030
Patents (1 active)
US8946262
Expires Feb 12, 2030
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.